STOCK TITAN

Director Jeffrey Mirviss granted 5,603 RSUs at CONMED (NYSE: CNMD)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mirviss Jeffrey B. reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp director Jeffrey B. Mirviss reported a grant of 5,603 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock and was awarded under the company’s 2025 Long-Term Incentive Plan. The RSUs generally vest 100% after one year, and Mirviss now holds 5,603 RSUs directly as reported in this filing. This is a compensation-related equity award rather than an open-market stock purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Mirviss Jeffrey B.
Role null
Type Security Shares Price Value
Grant/Award RSUs (Restricted Stock Units) 5,603 $0.00 --
Holdings After Transaction: RSUs (Restricted Stock Units) — 5,603 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 5,603 units Grant to director Jeffrey B. Mirviss on 2026-07-01
Holdings after grant 5,603 RSUs Total RSUs reported following transaction
Exercise price $0.0000 per unit RSU grant price
Vesting schedule 100% after one year General RSU vesting period
Expiration date 2036-07-01 RSU expiration
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2025 Long-Term Incentive Plan financial
"subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan"
contingent right financial
"represents a contingent right to receive one share of common stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mirviss Jeffrey B.

(Last)(First)(Middle)
C/O CONMED CORPORATION
11311 CONCEPT BOULEVARD

(Street)
LARGO FLORIDA 33773

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
RSUs (Restricted Stock Units)$007/01/2026A5,60307/01/2027(1)07/01/2036Common Stock5,603$05,603D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
/s/ Thomas Fistek for Jeffrey B. Mirviss by Power of Attorney07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CONMED (CNMD) report for Jeffrey B. Mirviss?

CONMED reported that director Jeffrey B. Mirviss received a grant of 5,603 restricted stock units. These RSUs are a form of equity compensation and each unit represents a contingent right to receive one share of CONMED common stock, subject to vesting conditions.

How many RSUs did Jeffrey B. Mirviss receive from CONMED (CNMD)?

Jeffrey B. Mirviss received 5,603 restricted stock units from CONMED. After this grant, his reported holdings in these RSUs total 5,603 units, all held directly, reflecting the full amount of the newly awarded equity-based compensation.

When do Jeffrey B. Mirviss’s CONMED (CNMD) RSUs vest?

The RSUs granted to Jeffrey B. Mirviss generally vest 100% after a one-year period. This means he must remain eligible through that year before the units convert into CONMED common shares deliverable under the plan’s terms.

What does each RSU granted to Jeffrey B. Mirviss by CONMED (CNMD) represent?

Each restricted stock unit granted to Jeffrey B. Mirviss represents a contingent right to receive one share of CONMED common stock. Delivery of these shares depends on satisfying the vesting conditions set out in the 2025 Long-Term Incentive Plan.

Under which plan were Jeffrey B. Mirviss’s CONMED (CNMD) RSUs granted?

The 5,603 restricted stock units granted to Jeffrey B. Mirviss were issued under CONMED’s 2025 Long-Term Incentive Plan. This plan governs the terms, vesting schedule, and other conditions applicable to the equity awards he received.